Peptides > AOD9604
AOD9604
AOD9604, derived from the human growth hormone fragment 176-191 peptide with a di-sulfide bridge modification, is a modified version of hGH. Initially designed for its lipolytic (fat-burning) properties, AOD9604 has demonstrated promising results in research related to heart disease, osteoarthritis, and metabolic syndrome. AOD9604 has been found to promote lipolysis, the process of breaking down fat, and also inhibits lipogenesis in animal studies.
- Product Usage:
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.
PEPTIDE INDEX
» Adipotide (FTPP)
» AICAR
» AOD9604
» ARA-290
» Bronchogen
» BPC-157
» B7-33
» Cardiogen
» Cartalax
» Cerebrolysin (215mg/ml, 10ml)
» Chonluten
» CJC-1295 DAC
» Cortagen
» DSIP
» Epithalon (Epitalon)
» Follistatin-315
» Follistatin-344
» FOXO4-DRI
» hGH Fragment 176-191
» GHK Basic
» GHK-Cu (Copper Peptide)
» GHRP-2
» GHRP-6
» GHRH (GH-Releasing Hormone)
» Glutathione
» Gonadorelin (GnRH)
» Hexarelin
» Humanin
» Ipamorelin
» Kisspeptin-10
» KPV (ACTH (11-13) alpha-MSH)
» Liraglutide (GLP-1 Analogue)
» Livagen
» LL-37 (CAP-18)
» Melanotan 2 (Melanotan II)
» MGF (C-terminal)
» MK-677 (Ibutamoren)
» ModGRF 1-29 (CJC-1295 No DAC)
» MOTS-c
» N-Acetyl Epithalon Amidate
» N-Acetyl Selank Amidate
» N-Acetyl Semax Amidate
» NAD+
» Ovagen
» Oxytocin
» Pancragen
» PE-22-28
» PEG-MGF (Pegylated MGF)
» Pinealon
» PNC-27
» Prostamax
» PT-141 (Bremelanotide)
» P21 (P021)
» Selank
» Semaglutide (GLP-1 Analogue)
» Semax
» Sermorelin
» SS-31
» TB-500 (Thymosin Beta-4)
» Tesamorelin
» Testagen
» Thymagen
» Thymosin Alpha-1
» Thyrotropin-TRH
» Tirzepatide
» Triptorelin
» Vesugen
» Vesilute
» Vilon
» VIP (Vasoactive Intestinal Peptide)
» GHK-Cu
» Retatrutide
Introduction
AOD9604, derived from fragment 176-191, which in turn is a modified segment of human growth hormone (HGH), was initially developed as an anti-obesity medication due to its lipolytic (fat-burning) capabilities. What sets this peptide apart is its limited impact beyond fat reduction. AOD9604 does not seem to influence IGF-1 or insulin levels, making it a safe choice without a risk of promoting glucose intolerance or diabetes. Furthermore, there is no evidence to suggest that the body generates antibodies against AOD9604, as its structural similarity to HGH allows it to avoid triggering an immune response.
Structure
Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe Disulfide bridge Cys7-Cys15
Molecular Formula: C78H123N23O23S2
Molecular Weight: 1815.12 g/mol
PubChem CID: 16131447
CAS Number: 386264-39-7
Research
AOD9604 and Obesity
AOD9604 was initially designed as an HGH analogue with a specific focus on combating fat. In Australia, Phase 2b clinical trials involving 300 obese individuals were conducted, demonstrating that a 12-week regimen of daily peptide administration tripled weight loss compared to a placebo. Importantly, the rate of weight loss remained consistent throughout the trial, suggesting that resistance to the peptide is unlikely to develop, and longer-term treatment could lead to even more substantial weight loss.
Studies conducted in mice genetically predisposed to obesity suggest that AOD9604’s fat-reducing effects are not solely attributed to its impact on beta-3-adrenergic receptors found in white fat. Initially, it was believed that the peptide bound to these receptors, boosting metabolism in fat cells and transitioning them from storage to utilization. However, it has been observed that fat loss still occurs even in mice lacking these receptors when AOD9604 is administered. This suggests the involvement of additional mechanisms. Some theories propose that AOD9604 might indirectly trigger apoptosis, or programmed cell death, in white fat cells.
Joint Pain and Function
Studies conducted in rats have shown that direct injections of AOD9604 into arthritic joints can complement existing therapies, leading to improved pain management, reduced disability, and an enhanced quality of life. Both observable clinical examinations and microscopic assessments of cartilage in the affected joints suggest that AOD9604 effectively addresses the underlying causes of osteoarthritis. This peptide may serve both as a treatment and a preventive measure. While AOD9604 is effective in mitigating joint dysfunction independently, its efficacy is even greater when used in conjunction with other treatments. The precise mechanisms behind this synergy are not fully understood, but further research employing this peptide may uncover innovative pathways for enhancing cartilage growth—a challenging clinical issue.
B. BMI Reduction Analysis: This graph portrays a compelling perspective on the impact of adipotide treatment on BMI reduction compared to the control group. The blue line represents the control group’s BMI, while the red line signifies the BMI of individuals who received adipotide treatment. The notable reduction in BMI within the treatment group serves as a compelling testament to the efficacy of adipotide in positively influencing body mass index, further substantiating its potential as a valuable tool in managing weight and related health parameters.
AOD9604 and Heart Disease
While AOD9604’s primary role is in reducing fat and weight loss, there is emerging evidence suggesting that it may offer beneficial effects on the heart beyond its fat-reduction capabilities. It is speculated that the peptide might directly influence metabolism in a way that reduces complications unrelated to obesity. This concept is not unprecedented, as certain drugs like pioglitazone and acipimox have shown the ability to alleviate metabolic issues without addressing obesity itself. It is believed that the alternative pathway through which AOD9604 promotes fat loss, one that doesn’t rely on beta-3-adrenergic receptor activation, may contribute to improving metabolic parameters while simultaneously aiding in fat loss.
AOD9604 is known for its minimal side effects, strong oral and subcutaneous bioavailability in mice. However, it’s important to note that the dosage per kilogram used in mice cannot be directly applied to humans. It’s crucial to understand that AOD9604 available at Peptide Sciences is intended strictly for educational and scientific research purposes and should not be used for human consumption. Therefore, if you are not a licensed researcher, it is advisable not to purchase AOD9604.
Article Author
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The product information featured on this website pertains exclusively to in-vitro studies. In-vitro studies, also known as ‘in glass’ studies, are conducted outside of living organisms. It’s important to emphasize that these products do not constitute medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical conditions, ailments, or diseases. It is crucial to note that the introduction of these products into the bodies of humans or animals is strictly prohibited by law.
